Performance Status is an Important Prognostic Factor in Second Line Treatment of Pancreaticobiliary Adenocarcinoma

Basit Öğe Kaydı
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorErdogan, Bulent
dc.contributor.authorTurkmen, Esma
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorTanriverdi, Ozgur
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T11:12:02Z
dc.date.available2024-06-12T11:12:02Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/Aims: To define the factors related with disease control and survival in patients with pancreaticobiliary adenocarcinoma treated with second-line therapy. Methodology: We retropectively reviewed the data of 39 pancreaticobiliary adenocarcinoma patients treated with second-line chemotherapy between 2000 and 2012. Age, gender, origin of tumor, location of tumor, stage at diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status, progression site, progression free survival (PFS) for first-line therapy, disease control at first-line therapy and chemotherapy protocols are analyzed for disease control rate, PFS and overall survival (OS). Results: Disease control was recorded in 21 (53.8%) patients (20 stable disease, 1 partial response). Disease control rate was higher in patients with good performance status (p=0.03). Disease control at first-line therapy was not a predictor of disease control at second-line (p=0.6). Response to first-line therapy and other prognostic factors was not related with disease control. Progression free survival and OS was significantly longer in patients with good ECOG performance status (0-1) (p=0.01, p=0.006). Choice of chemotherapy (single agent or combination) and other factors did not have any impact on PFS and OS. In multivariate analysis; disease control was independent prognostic factor for both PFS and OS (p<0.001), (p<0.001). Conclusions: Disease control and performance status are two important prognostic factors. Chemotherapy regimen has no impact on disease control and survival. Salvage chemotherapy can be considered for patients with good performance status whether they are resistant to first-line therapy or not.en_US
dc.identifier.doi10.5754/hge13269
dc.identifier.endpage1483en_US
dc.identifier.issn0172-6390
dc.identifier.issue126en_US
dc.identifier.pmid23933941en_US
dc.identifier.scopus2-s2.0-84885708799en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1479en_US
dc.identifier.urihttps://doi.org/10.5754/hge13269
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23008
dc.identifier.volume60en_US
dc.identifier.wosWOS:000330327800043en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPancreaticobiliary Adenocarcinomaen_US
dc.subjectSecond-Line Chemotherapyen_US
dc.subjectDisease Controlen_US
dc.subjectPerformance Statusen_US
dc.subjectPhase-Iii Trialen_US
dc.subject2nd-Line Chemotherapyen_US
dc.subjectPretreated Patientsen_US
dc.subject1st-Line Treatmenten_US
dc.subjectPlus Gemcitabineen_US
dc.subjectCanceren_US
dc.subjectCapecitabineen_US
dc.subjectOxaliplatinen_US
dc.subjectCisplatinen_US
dc.subjectSurvivalen_US
dc.titlePerformance Status is an Important Prognostic Factor in Second Line Treatment of Pancreaticobiliary Adenocarcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu